CD8A and neoplasm: Consistent with the increased expression of effector molecules (Figure 4C), greater numbers of CD8+ T cells specific for the previously identified MHC class I–restricted MOC22-specific neoantigen mICAM308-315 and the shared antigen p15E604-611 were identified in TIL from treated tumors compared with control, indicating that reinvigorated TEX subsets enriched after NHS–rmIL-12 treatment may be tumor antigen specific.